Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress

CAR T-cell therapy for triple-negative breast cancer: Where we are

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies

Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

CAR T cells in solid tumors: challenges and opportunities

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook

Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Bright future or blind alley? CAR-T cell therapy for solid tumors

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Current progress in CAR-T cell therapy for tumor treatment